运动方式-剂量组合对帕金森病认知功能的影响:贝叶斯剂量-反应系统审查和元分析
1Jiangsu University, Zhenjiang, China.
Archives of gerontology and geriatrics
|August 23, 2025
概括
对于帕金森病患者来说,最有效的运动剂量是每周大约890MET·min,效果在每周500-1000MET·min之间. 多组件和心身运动是最有效的.
科学领域:
- 神经科学
- 运动生理学
- 老年学
背景情况:
- 帕金森病 (PD) 显著影响认知功能.
- 非药物干预,特别是运动,对于治疗PD症状至关重要.
- 对于PD患者进行认知增强的最佳运动策略尚不清楚.
研究的目的:
- 确定改善帕金森病 (PD) 认知功能的最有效的运动方式.
- 为了确定PD患者对认知效益的最佳运动剂量范围.
- 开发用于PD运动干预的剂量反应模型.
主要方法:
- 33项随机对照试验 (RCT) 的系统性审查和贝叶斯剂量反应网络元分析,涉及1256名PD患者.
- 使用MET·min/week标准化的运动剂量,并使用GRADE框架进行评估.
- 在九种运动方式中模拟非线性认知效应.
主要成果:
- 运动剂量与认知结果之间存在一个反转的U形关系,峰值约为890MET·min/周.
- 对于PD患者的认知改善,最佳剂量范围为500-1000MET/分/周.
- 多组件训练和心身炼显示出最一致的认知效益;虚拟现实和有氧步行具有特定的效益,而骑自行车,舞蹈和抵抗训练没有显示出一致的效果.
结论:
- 这项研究提供了第一个用于帕金森病 (PD) 认知增强的剂量模式反应模型.
- 这些研究结果支持针对PD认知健康的定制,精确的运动干预措施.
- 这些结果对其他神经退行性疾病的非药理策略有潜在的影响.
更多相关视频
相关概念视频
01:24Parkinson's Disease: Treatment
377
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
377
01:15Parkinson's Disease: Overview
703
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
703
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
01:20Exercise and Cardiovascular Response
1.1K
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
1.1K
01:22Dose-Response Relationship: Potency and Efficacy
5.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.2K